Fig. 1 <u>Bis In<sup>3+</sup> IMP 274</u>

Fig. 2 Bis In<sup>3+</sup> IMP 274 (SN-38 analog)

Fig. 3 Bis In<sup>3+</sup> IMP 274 (SN-38 analog with penicillamine linker)

Fig. 4 Bis In<sup>3+</sup> IMP 274 (SN-38 analog linked to a cysteine using a hindered ester)

Fig. 6 Bis In<sup>3+</sup> IMP 224

Fig. 7 HPLC analysis (Reverse Phase) of <sup>111</sup>In-Labeled IMP 274




Fig. 8 HPLC Analysis (Size Exclusion) of 111 In-Labeled IMP 274




Fig. 9A <u>HPLC analysis (Reverse Phase) of</u>

111 In-Labeled IMP 274 in Mouse Serum




Fig. 9B <u>HPLC analysis (Reverse Phase) of</u>

111 In-Labeled IMP 274 in Mouse Serum




Fig. 10A <u>HPLC analysis (Reverse Phase) of</u>

111 In-Labeled IMP 274 in Human Serum




Fig. 10B <u>HPLC analysis (Reverse Phase) of</u>

111 In-Labeled IMP 274 in Human Serum




Fig. 11 HPLC analysis (Size Exclusion) of <sup>111</sup>In-Labeled IMP 274 in Mouse Serum containing bsAb 734xhMN14




Fig. 12 <u>HPLC analysis (Size Exclusion) of <sup>111</sup>In-Labeled IMP 274 in</u>

<u>Human Serum containing bsAb 734xhMN14</u>






Fig. 13 Stability of IMP 294 (A) and IMP 295 (B) in PBS at 25°C

Over 7 Days






## Fig. 14 Pre-targeting in SCID Mice

Α.

SCID Mice Inoculated i.v. with 1.5 x 10 <sup>7</sup> Daudi Cells					
Group	(N)	Treatment	Ratio	Dose	Schedule
l	9	LL2x734 IMP-225	(1:1)	300 μg (3 x 10 <sup>-9</sup> moles) ~6 μg (3 x 10 <sup>-9</sup> moles)	Days 1, 3, 7, 9 Days 2, 4, 8, 10
II	8	IMP-225 Alone	N/A	~30 μg (1.5 x 10 <sup>-8</sup> moles)	Days 2, 4, 8, 10

B.






Fig. 15 Synthesis of DTPA Precursor and DTPA (Three Step Method)

Fig. 16 Synthesis of DTPA Precursor and DTPA (Four Step Method)